Opinion|Videos|November 20, 2026

Squamous Biology, Emerging Targets, and TROP2 Antibody-Drug Conjugates

Vamsidhar Velcheti, MD, explains that squamous non-small cell lung cancer lacks treatable drivers, pointing instead to immune-resistance biology such as NRF2 pathway upregulation and investigational KEAP1 modulators and glutaminase inhibitors.

Vamsidhar Velcheti, MD, explains that squamous non-small cell lung cancer lacks treatable drivers, pointing instead to immune-resistance biology such as NRF2 pathway upregulation and investigational KEAP1 modulators and glutaminase inhibitors. Balazs Halmos, MD, notes that common alterations such as TP53, CDKN2A, and PIK3CA have not yielded targets. Alexander Spira, MD, PhD, FACP, links the high neoantigen load of smoking-related tumors to immunotherapy opportunities and highlights MTAP deletion as a biomarker for new agents with modest single-agent responses, adding that new drugs must outperform rather than match docetaxel. Turning to antibody-drug conjugates (ADCs), Dr. Spira recalls early excitement with datopotamab deruxtecan, followed by worse outcomes than docetaxel in squamous disease. Dr. Velcheti suspects the topoisomerase payload played a role and says sacituzumab tirumotecan appears more promising. Dr. Spira emphasizes that the antibody, linker, and payload make ADCs different from one another. Dr. Halmos notes several positive randomized trials of sacituzumab tirumotecan, and Dr. Velcheti adds that more global data are needed.


Related to this article